An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
A phase 3 trial of Atezolizumab, Bevacizumab, Pemetrexed and Enzalutamide in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) is a phase 3 interventional study registered as NCT05112965 by Hoffmann-La Roche, with 49 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Atezolizumab, Bevacizumab, Pemetrexed, Paclitaxel and Enzalutamide.
Similar pages
not linked directly; found by shared links- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Shares Pemetrexed, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.